{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:42Z","timestamp":1792191942480,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108430037"],"award-info":[{"award-number":["202108430037"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The \u03b2\n                      <jats:sub>3<\/jats:sub>\n                      -agonist vibegron is available for treatment of storage symptoms, but in vitro data in human tissues are not yet available. Based on findings with mirabegron, mechanisms other than inhibition of voiding contractions in the detrusor may account for symptom improvements, and off-target effects in the prostate and bladder appear possible. Here, we examined vibegron effects in human detrusor and prostate tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Detrusor and prostate tissues were obtained from radical cystectomy, radical prostatectomy and laser enucleation. Concentration response curves for agonists and frequence response curves for electric field stimulation (EFS) were examined in organ baths with 0.01, 0.1, 1 and 10\u00a0\u00b5M vibegron or vehicle control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In detrusor tissues, 10\u00a0\u00b5M vibegron reduced EFS-induced contractions by half, while no biologically relevant inhibitions occurred with lower concentrations or with carbachol- or methacholine-induced contractions. Pretensions before contractions were relaxed\u2009&gt;\u200920% by 0.1\u201310\u00a0\u00b5M vibegron. EFS-induced contractions were halved by 10\u00a0\u00b5M vibegron in prostatectomized tissues, but unaffected by lower concentrations and in laser-enucleated prostate tissues. Additionally, 10\u00a0\u00b5M vibegron right-shifted concentration response curves and increased the EC\n                      <jats:sub>50<\/jats:sub>\n                      values for noradrenaline, phenylephrine and methoxamine in prostatectomized and laser-enucleated prostate tissues, while lower concentrations had no consistent effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Similar to mirabegron, improvements of storage symptoms by vibegron involve mechanisms beyond inhibition of voiding contractions. Off-target effects occur with 10\u00a0\u00b5M, and include inhibition of neurogenic contractions and antagonism of prostatic \u03b1\n                      <jats:sub>1A<\/jats:sub>\n                      -adrenoceptors. Vibegron effects in the prostate may differ between patients with low BPH progression, and patients needing surgery for BPH.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00210-025-04762-z","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:10:50Z","timestamp":1762189850000},"page":"5463-5481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues"],"prefix":"10.1007","volume":"399","author":[{"given":"Sheng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brandstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwafemi E.","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo Federico","family":"Stadelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-6727","authenticated-orcid":false,"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"4762_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","volume":"62","author":"N Aizawa","year":"2012","unstructured":"Aizawa N, Homma Y, Igawa Y (2012) Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol 62:1165\u20131173. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.056","journal-title":"Eur Urol"},{"key":"4762_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/nau.22571","volume":"34","author":"N Aizawa","year":"2015","unstructured":"Aizawa N, Homma Y, Igawa Y (2015) Effects of L-arginine, mirabegron, and oxybutynin on the primary bladder afferent nerve activities synchronized with reflexic, rhythmic bladder contractions in the rat. Neurourol Urodyn 34:368\u2013374. https:\/\/doi.org\/10.1002\/nau.22571","journal-title":"Neurourol Urodyn"},{"key":"4762_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.eururo.2008.11.011","volume":"55","author":"A Alcaraz","year":"2009","unstructured":"Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R (2009) Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a Literature Review Eur Urol 55:864\u2013873. https:\/\/doi.org\/10.1016\/j.eururo.2008.11.011","journal-title":"Findings of a Literature Review Eur Urol"},{"issue":"Suppl 2","key":"4762_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/bph.16177","volume":"180","author":"SPH Alexander","year":"2023","unstructured":"Alexander SPH et al (2023) The concise guide to PHARMACOLOGY 2023\/24: G protein-coupled receptors. Br J Pharmacol 180(Suppl 2):S23\u2013S144. https:\/\/doi.org\/10.1111\/bph.16177","journal-title":"Br J Pharmacol"},{"key":"4762_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","volume":"173","author":"EC Alexandre","year":"2016","unstructured":"Alexandre EC et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol 173:415\u2013428. https:\/\/doi.org\/10.1111\/bph.13367","journal-title":"Br J Pharmacol"},{"key":"4762_CR6","doi-asserted-by":"publisher","unstructured":"Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148:1549\u20131557; discussion 1564 https:\/\/doi.org\/10.1016\/s0022-5347(17)36966-5","DOI":"10.1016\/s0022-5347(17)36966-5"},{"key":"4762_CR7","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.curtheres.2022.100674","volume":"96","author":"BM Brucker","year":"2022","unstructured":"Brucker BM, King J, Mudd PN Jr, McHale K (2022) Selectivity and Maximum Response of Vibegron and Mirabegron for beta(3)-Adrenergic Receptors. Curr Ther Res Clin Exp 96:100674. https:\/\/doi.org\/10.1016\/j.curtheres.2022.100674","journal-title":"Curr Ther Res Clin Exp"},{"key":"4762_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pros.22930","volume":"75","author":"FB Calmasini","year":"2015","unstructured":"Calmasini FB et al (2015) The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? Prostate 75:440\u2013447. https:\/\/doi.org\/10.1002\/pros.22930","journal-title":"Prostate"},{"key":"4762_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.116.237313","volume":"360","author":"J Di Salvo","year":"2017","unstructured":"Di Salvo J et al (2017) Pharmacological characterization of a novel beta 3 adrenergic agonist, Vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther 360:346\u2013355. https:\/\/doi.org\/10.1124\/jpet.116.237313","journal-title":"J Pharmacol Exp Ther"},{"key":"4762_CR10","doi-asserted-by":"publisher","first-page":"e0170726","DOI":"10.1371\/journal.pone.0170726","volume":"12","author":"MJ Drake","year":"2017","unstructured":"Drake MJ et al (2017) Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS\u2122 for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE\/NEPTUNE II randomized controlled studies. PLoS ONE 12:e0170726. https:\/\/doi.org\/10.1371\/journal.pone.0170726","journal-title":"PLoS ONE"},{"key":"4762_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05487-7","volume":"43","author":"B Ebner","year":"2025","unstructured":"Ebner B et al (2025) Discrepancies between physician-assessed and patient-reported complications after cystectomy - a prospective analysis. World J Urol 43:115. https:\/\/doi.org\/10.1007\/s00345-025-05487-7","journal-title":"World J Urol"},{"key":"4762_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"SD Edmondson","year":"2016","unstructured":"Edmondson SD et al (2016) Discovery of Vibegron: a potent and selective \u03b23Adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59:609\u2013623. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01372","journal-title":"J Med Chem"},{"key":"4762_CR13","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/nau.23557","volume":"37","author":"M Grabbert","year":"2018","unstructured":"Grabbert M, Buchner A, Butler-Ransohoff C, Kretschmer A, Stief CG, Bauer RM (2018) Long-term functional outcome analysis in a large cohort of patients after radical prostatectomy. Neurourol Urodyn 37:2263\u20132270. https:\/\/doi.org\/10.1002\/nau.23557","journal-title":"Neurourol Urodyn"},{"key":"4762_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas S et al (2023) Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol 84:207\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008","journal-title":"Eur Urol"},{"key":"4762_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/164_2023_678","volume":"285","author":"M Hennenberg","year":"2024","unstructured":"Hennenberg M, Michel MC (2024) Adrenoceptors in the lower urinary tract. Handb Exp Pharmacol 285:333\u2013367. https:\/\/doi.org\/10.1007\/164_2023_678","journal-title":"Handb Exp Pharmacol"},{"key":"4762_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00210-022-02218-2","volume":"395","author":"R Huang","year":"2022","unstructured":"Huang R, Li B, Tamalunas A, Waidelich R, Stief CG, Hennenberg M (2022a) Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729. Naunyn Schmiedebergs Arch Pharmacol 395:471\u2013485. https:\/\/doi.org\/10.1007\/s00210-022-02218-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4762_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.666047","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R et al (2021) Concentration-dependent alpha1-Adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by Mirabegron in the human prostate. Front Pharmacol 12:666047. https:\/\/doi.org\/10.3389\/fphar.2021.666047","journal-title":"Front Pharmacol"},{"key":"4762_CR18","doi-asserted-by":"publisher","first-page":"115148","DOI":"10.1016\/j.bcp.2022.115148","volume":"202","author":"R Huang","year":"2022","unstructured":"Huang R, Tamalunas A, Waidelich R, Strittmatter F, Stief CG, Hennenberg M (2022) Antagonism of alpha1-adrenoceptors by beta3-adrenergic agonists: Structure-function relations of different agonists in prostate smooth muscle contraction. Biochem Pharmacol 202:115148. https:\/\/doi.org\/10.1016\/j.bcp.2022.115148","journal-title":"Biochem Pharmacol"},{"key":"4762_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/jpet.121.001029","volume":"381","author":"R Huang","year":"2022","unstructured":"Huang R, Tamalunas A, Waidelich R, Strittmatter F, Stief CG, Hennenberg M (2022c) Inhibition of full smooth muscle contraction in isolated human detrusor tissues by Mirabegron is limited to off-target inhibition of neurogenic contractions. J Pharmacol Exp Ther 381:176\u2013187. https:\/\/doi.org\/10.1124\/jpet.121.001029","journal-title":"J Pharmacol Exp Ther"},{"key":"4762_CR20","doi-asserted-by":"publisher","unstructured":"Huang R, Yu Q, Tamalunas A, Stief CG, Hennenberg M (2024) Ligand-receptor interactions and structure-function relationships in off-target binding of the beta(3)-adrenergic agonist mirabegron to alpha(1A)-Adrenergic receptors. Int J Mol Sci 25 https:\/\/doi.org\/10.3390\/ijms25137468","DOI":"10.3390\/ijms25137468"},{"key":"4762_CR21","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bph.14658","volume":"176","author":"Y Igawa","year":"2019","unstructured":"Igawa Y, Aizawa N, Michel MC (2019) Beta3 -adrenoceptors in the normal and diseased urinary bladder-what are the open questions? Br J Pharmacol 176:2525\u20132538. https:\/\/doi.org\/10.1111\/bph.14658","journal-title":"Br J Pharmacol"},{"key":"4762_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.euros.2025.03.013","volume":"75","author":"P Julieb\u00f8-Jones","year":"2025","unstructured":"Julieb\u00f8-Jones P, Roth I, Moen CA, Gjengst\u00f8 P, Beisland C (2025) National trends in medication prescriptions for male lower urinary tract symptoms and erectile dysfunction: findings from the Norwegian prescription database. Eur Urol Open Sci 75:89\u201393. https:\/\/doi.org\/10.1016\/j.euros.2025.03.013","journal-title":"Eur Urol Open Sci"},{"key":"4762_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1756287220974130","volume":"12","author":"TW Kang","year":"2020","unstructured":"Kang TW, Chung HC (2020) Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy. Ther Adv Urol 12:1756287220974130. https:\/\/doi.org\/10.1177\/1756287220974130","journal-title":"Ther Adv Urol"},{"issue":"1","key":"4762_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88884-7","volume":"15","author":"P Keller","year":"2025","unstructured":"Keller P et al (2025a) Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative \u03b11-blocker treatment in patients with and without catheterization. Sci Rep 15(1):4985. https:\/\/doi.org\/10.1038\/s41598-025-88884-7","journal-title":"Sci Rep"},{"key":"4762_CR25","doi-asserted-by":"publisher","first-page":"1612954","DOI":"10.3389\/fphys.2025.1612954","volume":"16","author":"P Keller","year":"2025","unstructured":"Keller P et al (2025b) Voiding symptom severity varies independently from non-adrenergic prostate smooth muscle contractions in patients undergoing surgery for benign prostatic hyperplasia. Front Physiol 16:1612954. https:\/\/doi.org\/10.3389\/fphys.2025.1612954","journal-title":"Front Physiol"},{"key":"4762_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cpdd.1169","volume":"11","author":"J King","year":"2022","unstructured":"King J, Walker A, Aikin D, Haag-Molkenteller C, Kankam M (2022) Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults. Clin Pharmacol Drug Dev 11:1349\u20131355. https:\/\/doi.org\/10.1002\/cpdd.1169","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4762_CR27","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel W et al (2012) Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34:2144\u20132160. https:\/\/doi.org\/10.1016\/j.clinthera.2012.09.010","journal-title":"Clin Ther"},{"issue":"Suppl 9","key":"4762_CR28","first-page":"S3","volume":"6","author":"H Lepor","year":"2004","unstructured":"Lepor H (2004) Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 6(Suppl 9):S3\u2013S10","journal-title":"Rev Urol"},{"key":"4762_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.urology.2018.03.038","volume":"117","author":"CH Liao","year":"2018","unstructured":"Liao CH, Kuo HC (2018) Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction. Urology 117:115\u2013119. https:\/\/doi.org\/10.1016\/j.urology.2018.03.038","journal-title":"Urology"},{"key":"4762_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-016-0165-3","volume":"16","author":"T Matsuo","year":"2016","unstructured":"Matsuo T, Miyata Y, Kakoki K, Yuzuriha M, Asai A, Ohba K, Sakai H (2016) The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with \u03b11-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol 16:45. https:\/\/doi.org\/10.1186\/s12894-016-0165-3","journal-title":"BMC Urol"},{"key":"4762_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bph.13379","volume":"173","author":"MC Michel","year":"2016","unstructured":"Michel MC (2016) How beta3 -adrenoceptor-selective is mirabegron? Br J Pharmacol 173:429\u2013430. https:\/\/doi.org\/10.1111\/bph.13379","journal-title":"Br J Pharmacol"},{"key":"4762_CR32","doi-asserted-by":"publisher","first-page":"173632","DOI":"10.1016\/j.ejphar.2020.173632","volume":"889","author":"MC Michel","year":"2020","unstructured":"Michel MC (2020) alpha1-adrenoceptor activity of beta-adrenoceptor ligands - An expected drug property with limited clinical relevance. Eur J Pharmacol 889:173632. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173632","journal-title":"Eur J Pharmacol"},{"key":"4762_CR33","doi-asserted-by":"publisher","unstructured":"Michel MC, Arioglu-Inan E, Hennenberg M (2025) beta(3)-Adrenoceptor agonist effects on the urinary bladder beyond detrusor relaxation neurourol. Urodyn https:\/\/doi.org\/10.1002\/nau.70043","DOI":"10.1002\/nau.70043"},{"issue":"4","key":"4762_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel MC et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev 75(4):554\u2013674. https:\/\/doi.org\/10.1124\/pharmrev.121.000523","journal-title":"Pharmacol Rev"},{"key":"4762_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/mol.119.118927","volume":"97","author":"MC Michel","year":"2020","unstructured":"Michel MC, Murphy TJ, Motulsky HJ (2020) New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. Mol Pharmacol 97:49\u201360. https:\/\/doi.org\/10.1124\/mol.119.118927","journal-title":"Mol Pharmacol"},{"key":"4762_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1446831","volume":"15","author":"AE Muderrisoglu","year":"2024","unstructured":"Muderrisoglu AE et al (2024) Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron. Front Pharmacol 15:1446831. https:\/\/doi.org\/10.3389\/fphar.2024.1446831","journal-title":"Front Pharmacol"},{"key":"4762_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","volume":"82","author":"AK Nambiar","year":"2022","unstructured":"Nambiar AK et al (2022) European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol 82:49\u201359. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.045","journal-title":"Eur Urol"},{"key":"4762_CR38","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","volume":"190","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE (2013) Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 190:1320\u20131327. https:\/\/doi.org\/10.1016\/j.juro.2013.05.062","journal-title":"J Urol"},{"key":"4762_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrurol.2012.192","volume":"10","author":"DD Orsted","year":"2013","unstructured":"Orsted DD, Bojesen SE (2013) The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 10:49\u201354. https:\/\/doi.org\/10.1038\/nrurol.2012.192","journal-title":"Nat Rev Urol"},{"key":"4762_CR40","doi-asserted-by":"publisher","unstructured":"Pradidarcheep W, Wallner C, Dabhoiwala NF, Lamers WH (2011) Anatomy and histology of the lower urinary tract. Handb Exp Pharmacol:117\u2013148 https:\/\/doi.org\/10.1007\/978-3-642-16499-6_7","DOI":"10.1007\/978-3-642-16499-6_7"},{"key":"4762_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/jpet.113.207340","volume":"347","author":"P Sadananda","year":"2013","unstructured":"Sadananda P, Drake MJ, Paton JF, Pickering AE (2013) A functional analysis of the influence of beta3-adrenoceptors on the rat micturition cycle. J Pharmacol Exp Ther 347:506\u2013515. https:\/\/doi.org\/10.1124\/jpet.113.207340","journal-title":"J Pharmacol Exp Ther"},{"key":"4762_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3892\/mmr.2011.647","volume":"5","author":"Z Shaikhibrahim","year":"2012","unstructured":"Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S, Wernert N (2012) The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Mol Med Rep 5:313\u2013316. https:\/\/doi.org\/10.3892\/mmr.2011.647","journal-title":"Mol Med Rep"},{"key":"4762_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diff.2017.07.005","volume":"96","author":"DW Strand","year":"2017","unstructured":"Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG (2017) Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96:49\u201361. https:\/\/doi.org\/10.1016\/j.diff.2017.07.005","journal-title":"Differentiation"},{"key":"4762_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.urology.2023.02.014","volume":"175","author":"A Tamalunas","year":"2023","unstructured":"Tamalunas A et al (2023) Efficacy, efficiency, and safety of en-bloc vs three-lobe enucleation of the prostate: a propensity score-matched analysis. Urology 175:48\u201355. https:\/\/doi.org\/10.1016\/j.urology.2023.02.014","journal-title":"Urology"},{"key":"4762_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/luts.12404","volume":"14","author":"A Tamalunas","year":"2022","unstructured":"Tamalunas A, Westhofen T, Schott M, Keller P, Atzler M, Stief CG, Magistro G (2022) Holmium laser enucleation of the prostate: a truly size-independent method? LUTS: Lower Urinary Tract Symptoms 14:17\u201326. https:\/\/doi.org\/10.1111\/luts.12404","journal-title":"LUTS: Lower Urinary Tract Symptoms"},{"key":"4762_CR46","unstructured":"U.S. Food and Drug Administration CfDEaR (2019) Clinical pharmacology review: Vibegron (GEMTESA), NDA 213006. . https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213006Orig1s000ClinPharmR.pdf."},{"key":"4762_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.urology.2023.08.020","volume":"182","author":"T Westhofen","year":"2023","unstructured":"Westhofen T et al (2023) The impact of laser energy on functional outcome following holmium laser enucleation of the prostate. Urology 182:190\u2013195. https:\/\/doi.org\/10.1016\/j.urology.2023.08.020","journal-title":"Urology"},{"key":"4762_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urology.2024.04.020","volume":"192","author":"T Westhofen","year":"2024","unstructured":"Westhofen T et al (2024a) Impact of preoperative LUTS on health-related quality of life following radical prostatectomy: a propensity score matched longitudinal study. Urology 192:52\u201358. https:\/\/doi.org\/10.1016\/j.urology.2024.04.020","journal-title":"Urology"},{"key":"4762_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05108-9","volume":"42","author":"T Westhofen","year":"2024","unstructured":"Westhofen T et al (2024) The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy - a propensity score matched longitudinal study. World J Urol 42:432. https:\/\/doi.org\/10.1007\/s00345-024-05108-9","journal-title":"World J Urol"},{"key":"4762_CR50","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/iju.14696","volume":"28","author":"S Yamada","year":"2021","unstructured":"Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Kagota S, Shinozuka K (2021a) Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder. Int J Urol 28:1298\u20131303. https:\/\/doi.org\/10.1111\/iju.14696","journal-title":"Int J Urol"},{"key":"4762_CR51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.120.000301","volume":"377","author":"S Yamada","year":"2021","unstructured":"Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Wakuda H, Shinozuka K (2021b) Possible involvement of muscarinic receptor blockade in Mirabegron therapy for patients with overactive bladder. J Pharmacol Exp Ther 377:201\u2013206. https:\/\/doi.org\/10.1124\/jpet.120.000301","journal-title":"J Pharmacol Exp Ther"},{"key":"4762_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290685","volume":"18","author":"S Yamamoto","year":"2023","unstructured":"Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T (2023) Vibegron shows high selectivity and potent agonist activity for \u03b23-adrenoceptors, irrespective of receptor density. PLoS ONE 18:e0290685. https:\/\/doi.org\/10.1371\/journal.pone.0290685","journal-title":"PLoS ONE"},{"key":"4762_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2206-y","volume":"18","author":"GJ Young","year":"2017","unstructured":"Young GJ, Lewis AL, Lane JA, Winton HL, Drake MJ, Blair PS (2017) Statistical analysis plan for the urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). Trials 18:455. https:\/\/doi.org\/10.1186\/s13063-017-2206-y","journal-title":"Trials"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04762-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04762-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04762-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:19:23Z","timestamp":1775099963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04762-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4762"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04762-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee at the faculty of medicine of the Ludwig-Maximilians University, Munich, Germany (August 30, 2024, 24\u20130736).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. All samples and data were collected and analyzed anonymously.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}